Naveen Kumar Devanga Ragupathi
Overview
Explore the profile of Naveen Kumar Devanga Ragupathi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sithu Shein A, Wannigama D, Hurst C, Monk P, Amarasiri M, Wongsurawat T, et al.
Sci Rep
. 2024 Nov;
14(1):28992.
PMID: 39578508
The increasing occurrence of hospital-associated infections, particularly bacteremia, caused by extensively drug-resistant (XDR) carbapenemase-producing colistin-resistant Klebsiella pneumoniae highlights a critical requirement to discover new therapeutic alternatives. Bacteriophages having host-specific bacteriolytic...
2.
Sithu Shein A, Wannigama D, Hurst C, Monk P, Amarasiri M, Badavath V, et al.
Biomed Pharmacother
. 2024 Nov;
168:115793.
PMID: 39491417
Given the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance...
3.
Ragupathi N, Muthuirulandi Sethuvel D, Ganesan A, Murugan D, Baskaran A, Wannigama D, et al.
Sci Rep
. 2024 Oct;
14(1):23572.
PMID: 39384811
Klebsiella pneumoniae has been identified as one of the most important opportunistic pathogens responsible for nosocomial infections. Antibiotic resistance and the ability to form biofilms are the two main factors...
4.
Wannigama D, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Besa J, et al.
Lancet Infect Dis
. 2024 Aug;
24(10):e610-e613.
PMID: 39181146
No abstract available.
5.
Wannigama D, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Chadsuthi S, et al.
Lancet Infect Dis
. 2024 Mar;
24(6):e348-e350.
PMID: 38522445
No abstract available.
6.
Wannigama D, Hurst C, Phattharapornjaroen P, Hongsing P, Sirichumroonwit N, Chanpiwat K, et al.
EClinicalMedicine
. 2024 Mar;
70:102517.
PMID: 38516100
Background: Repurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this...
7.
Wannigama D, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Chadsuthi S, et al.
J Travel Med
. 2024 Mar;
31(4).
PMID: 38438141
No abstract available.
8.
Anupong S, Chadsuthi S, Hongsing P, Hurst C, Phattharapornjaroen P, Rad S M A, et al.
iScience
. 2024 Feb;
27(3):109043.
PMID: 38375225
This study investigated the potential of using SARS-CoV-2 viral concentrations in dust as an additional surveillance tool for early detection and monitoring of COVID-19 transmission. Dust samples were collected from...
9.
Vazhappilly C, Siddiqui S, Anto R, Radhakrishnan R, Ragupathi N
Front Pharmacol
. 2023 Nov;
14:1320139.
PMID: 38027035
No abstract available.
10.
Wannigama D, Amarasiri M, Phattharapornjaroen P, Hurst C, Modchang C, Chadsuthi S, et al.
Lancet Infect Dis
. 2023 Oct;
23(11):e464-e466.
PMID: 37813112
No abstract available.